Literature DB >> 22993621

High ratio of interfollicular CD8/FOXP3-positive regulatory T cells is associated with a high FLIPI index and poor overall survival in follicular lymphoma.

Majda Saifi1, Aurélie Maran, Pierre Raynaud, Marie Christine Picot, Philippe Quittet, Guillaume Cartron, Jean François Rossi, Valérie Costes.   

Abstract

Several studies have highlighted the importance of the microenvironment in the behaviour of follicular lymphoma (FL). We conducted an immunohistochemical analysis to assess the role of different cell subpopulations, i.e. CD8, CD68 and forkhead box protein P3 (FOXP3)-positive regulatory T cells (Treg cells) in 84 lymph nodes of 58 patients with FL (58 at diagnosis, 26 at relapse). Since the overall effect of Tregs is considered to depend on their number in relation to CD8(+) effector T cells, we determined the corresponding ratio for each patient and correlated the results with clinical parameters. The interfollicular CD8/FOXP3(+) cell ratio was significantly higher in patients with histological grade 3 tumours (2.04 vs. 1.63) and with a high risk FLIPI index (2.99 vs. 1.53) compared to those with grade 1-2 tumours or a low-intermediate FLIPI index. Similar results were obtained for the follicular CD8(+)/FOXP3(+) cell ratio. The interfollicular CD8/FOXP3 ratio was found to have prognostic value [a 5-year overall survival (OS) of 82 vs. 59% for a ratio of ±1.68]. In addition, an interfollicular FOXP3(+) cell number of more than 86 cells/mm(2) was correlated with a more favourable outcome (p=0.03). When patients at diagnosis and relapse were compared, a significant difference (p=0.05) in the localization (interfollicular vs. intrafollicular) of FOXP3(+) cells was observed. The CD8/FOXP3 ratio in the interfollicular areas was significantly different (1.66 at diagnosis vs. 2.2 at relapse, p=0.05). The presence of a small number of FOXP3(+) cells with a high CD8/FOXP3 ratio is probably the indicator of an active immune response during tumour development, with lymphoma cells acting as targets or bystanders.

Entities:  

Year:  2010        PMID: 22993621      PMCID: PMC3446740          DOI: 10.3892/etm.2010.146

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

Review 1.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors.

Authors:  Daphne de Jong
Journal:  J Clin Oncol       Date:  2005-09-10       Impact factor: 44.544

2.  Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma.

Authors:  Annuska M Glas; Laurent Knoops; Leonie Delahaye; Marie José Kersten; Robby E Kibbelaar; Lodewyk A Wessels; Ryan van Laar; J Han J M van Krieken; Joke W Baars; John Raemaekers; Philip M Kluin; Laura J van't Veer; Daphne de Jong
Journal:  J Clin Oncol       Date:  2007-01-02       Impact factor: 44.544

3.  Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.

Authors:  Minna Taskinen; Marja-Liisa Karjalainen-Lindsberg; Sirpa Leppä
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

4.  Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.

Authors:  Tomás Alvaro; Marylène Lejeune; Ma Teresa Salvadó; Ramón Bosch; Juan F García; Joaquín Jaén; Alison H Banham; Giovanna Roncador; Carlos Montalbán; Miguel A Piris
Journal:  Clin Cancer Res       Date:  2005-02-15       Impact factor: 12.531

Review 5.  The biology of human lymphoid malignancies revealed by gene expression profiling.

Authors:  Louis M Staudt; Sandeep Dave
Journal:  Adv Immunol       Date:  2005       Impact factor: 3.543

Review 6.  The biology of the germinal center.

Authors:  Yasodha Natkunam
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

Review 7.  Differentiating germinal center-derived lymphomas through their cellular microenvironment.

Authors:  Antonino Carbone; Annunziata Gloghini; Antonello Cabras; Giuliano Elia
Journal:  Am J Hematol       Date:  2009-07       Impact factor: 10.047

8.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

9.  A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.

Authors:  Minna Taskinen; Marja-Liisa Karjalainen-Lindsberg; Heidi Nyman; Leena-Maija Eerola; Sirpa Leppä
Journal:  Clin Cancer Res       Date:  2007-10-01       Impact factor: 12.531

10.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Authors:  Alexandar Tzankov; Cecile Meier; Petra Hirschmann; Philip Went; Stefano A Pileri; Stephan Dirnhofer
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

View more
  7 in total

1.  Cellular and Molecular Profiling of Tumor Microenvironment and Early-Stage Lung Cancer.

Authors:  Radu Pirlog; Paul Chiroi; Ioana Rusu; Ancuta Maria Jurj; Liviuta Budisan; Cecilia Pop-Bica; Cornelia Braicu; Doinita Crisan; Jean-Christophe Sabourin; Ioana Berindan-Neagoe
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

Review 2.  Targeted Therapies in Adult B-Cell Malignancies.

Authors:  Jean-François Rossi
Journal:  Biomed Res Int       Date:  2015-09-06       Impact factor: 3.411

Review 3.  Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.

Authors:  Pauline Gravelle; Barbara Burroni; Sarah Péricart; Cédric Rossi; Christine Bezombes; Marie Tosolini; Diane Damotte; Pierre Brousset; Jean-Jacques Fournié; Camille Laurent
Journal:  Oncotarget       Date:  2017-07-04

Review 4.  Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells.

Authors:  Jean-François Rossi; Patrice Céballos; Zhao-Yang Lu
Journal:  Cancer Commun (Lond)       Date:  2019-06-14

5.  Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Wendy B C Stevens; Matias Mendeville; Robert Redd; Andrew J Clear; Reno Bladergroen; Maria Calaminici; Andreas Rosenwald; Eva Hoster; Wolfgang Hiddemann; Philippe Gaulard; Luc Xerri; Gilles Salles; Wolfram Klapper; Michael Pfreundschuh; Andrew Jack; Randy D Gascoyne; Yasodha Natkunam; Ranjana Advani; Eva Kimby; Birgitta Sander; Laurie H Sehn; Anton Hagenbeek; John Raemaekers; John Gribben; Marie José Kersten; Bauke Ylstra; Edie Weller; Daphne de Jong
Journal:  Haematologica       Date:  2017-04-14       Impact factor: 9.941

6.  MiR-7e-5p downregulation promotes transformation of low-grade follicular lymphoma to aggressive lymphoma by modulating an immunosuppressive stroma through the upregulation of FasL in M1 macrophages.

Authors:  Xiaoli Lou; Jianhong Fu; Xin Zhao; Xuemei Zhuansun; Chao Rong; Maomin Sun; Hui Niu; Lei Wu; Yongsheng Zhang; Lu An; Lingchuan Guo; Shan Wan; Shouli Wang
Journal:  J Exp Clin Cancer Res       Date:  2020-11-09

7.  The presence of tumour-infiltrating lymphocytes (TILs) and the ratios between different subsets serve as prognostic factors in advanced hypopharyngeal squamous cell carcinoma.

Authors:  Jie Wang; Shu Tian; Ji Sun; Jiahao Zhang; Lan Lin; Chunyan Hu
Journal:  BMC Cancer       Date:  2020-08-05       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.